Badanie skuteczności i bezpieczeństwa ruxolitinibu i metoksalenu u pacjentów z przewlekłą chorobą przeszczep przeciwko gospodarzowi oporną na sterydy

Chronic Graft-versus-Host Disease (cGvHD) is a condition that can occur after a bone marrow or stem cell transplant. It happens when the donated cells attack the recipient's body. This study focuses on patients with a specific type of this disease called steroid-refractory chronic Graft-versus-Host Disease (SR-cGvHD), which means the disease does not respond well to standard steroid treatments. The study aims to evaluate the safety and effectiveness of a combined treatment using ruxolitinib and a procedure known as extracorporeal photopheresis (ECP). Ruxolitinib is a medication taken in tablet form, while ECP is a process where blood is treated outside the body and then returned to the patient.

The purpose of the study is to see how well this combined treatment works for patients with SR-cGvHD. Participants will receive both ruxolitinib and ECP over a period of time. The study will monitor the patients' responses to the treatment, looking for improvements in their condition. The study will also assess the overall response rate at a specific point during the treatment, which is around the 25th week. This will help determine if the treatment is effective in reducing the symptoms of SR-cGvHD.

Throughout the study, patients will be closely observed to ensure their safety and to track any changes in their health. The study will also look at other factors, such as the ability to reduce steroid use and the overall survival of the patients. The results will provide valuable information on whether this treatment combination can be a beneficial option for those suffering from SR-cGvHD.